Combination of serum neurofilament light chain and serum cardiac troponin T as biomarkers improves diagnostic accuracy in amyotrophic lateral sclerosis

ObjectiveTo evaluate the diagnostic performance of serum neurofilament light chain (sNfL) and cardiac troponin T (cTnT) as biomarkers for amyotrophic lateral sclerosis (ALS) and to determine whether their combination improves diagnostic accuracy. MethodsWe retrospectively analyzed 293 ALS patients, 47 neurodegenerative disease controls and 24 healthy controls. An independent validation cohort of 501 ALS patients was additionally analyzed to confirm reproducibility of the results. Receiver operating characteristic (ROC) curve analysis was performed for sNfL, cTnT and their combination, and the area under the curve (AUC) was compared across groups. An ALS-specific cTnT cut-off of 8.35 ng/L was determined using the Youden index and applied in subgroup analyses, in which biomarker-negative ALS patients (normal sNfL and cTnT) were compared to biomarker-positive patients regarding disease duration and progression rate. ResultssNfL alone showed excellent performance in discriminating ALS patients from healthy controls (AUC = 0.951), but only moderate performance in discriminating neurodegenerative disease controls (AUC = 0.789). Combining sNfL and cTnT improved diagnostic accuracy for ALS over neurodegenerative disease controls, with a combined AUC of 0.866. Similar AUCs were observed in the validation cohort. Biomarker-negative ALS patients had a longer disease duration (73.0 vs. 18.0 months, p=0.0003) and a lower progression rate (0.19 vs. 0.70 points per months, p<0.0001) than biomarker-positive patients. InterpretationWhile sNfL alone performs well in distinguishing ALS from healthy controls, cTnT provides additional value in distinguishing ALS from disease controls. The combination of sNfL and cTnT improves diagnostic accuracy and may help identify clinically distinct ALS subgroups.